- Home
- NVNO vs UNCY Comparison
NVNO vs UNCY Comparison
Compare NVNO & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVNO
- UNCY
- Stock Information
- Founded
- NVNO 1987
- UNCY 2016
- Country
- NVNO United States
- UNCY United States
- Employees
- NVNO N/A
- UNCY N/A
- Industry
- NVNO Medical/Dental Instruments
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- NVNO Health Care
- UNCY Health Care
- Exchange
- NVNO Nasdaq
- UNCY Nasdaq
- Market Cap
- NVNO 58.9M
- UNCY 62.7M
- IPO Year
- NVNO N/A
- UNCY 2021
- Fundamental
- Price
- NVNO $3.15
- UNCY $0.53
- Analyst Decision
- NVNO
- UNCY Strong Buy
- Analyst Count
- NVNO 0
- UNCY 4
- Target Price
- NVNO N/A
- UNCY $5.50
- AVG Volume (30 Days)
- NVNO 147.8K
- UNCY 1.1M
- Earning Date
- NVNO 02-27-2025
- UNCY 03-27-2025
- Dividend Yield
- NVNO N/A
- UNCY N/A
- EPS Growth
- NVNO N/A
- UNCY N/A
- EPS
- NVNO N/A
- UNCY N/A
- Revenue
- NVNO N/A
- UNCY N/A
- Revenue This Year
- NVNO N/A
- UNCY N/A
- Revenue Next Year
- NVNO N/A
- UNCY N/A
- P/E Ratio
- NVNO N/A
- UNCY N/A
- Revenue Growth
- NVNO N/A
- UNCY N/A
- 52 Week Low
- NVNO $2.45
- UNCY $0.20
- 52 Week High
- NVNO $6.97
- UNCY $1.82
- Technical
- Relative Strength Index (RSI)
- NVNO 46.80
- UNCY 32.26
- Support Level
- NVNO $3.13
- UNCY $0.51
- Resistance Level
- NVNO $3.68
- UNCY $0.66
- Average True Range (ATR)
- NVNO 0.21
- UNCY 0.06
- MACD
- NVNO -0.01
- UNCY -0.02
- Stochastic Oscillator
- NVNO 8.20
- UNCY 7.48
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.